Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 4:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: transfusion therapy Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Utilizing A Single Session Problem-Solving Intervention With Caregivers of Pediatric Patients Receiving Chronic Transfusion to Treat Sickle Cell Disease

NCT04606160
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Single Session Problem-Solving Intervention
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
7 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 20, 2022 · Synced Sep 26, 2026, 4:26 PM EDT
Terminated Phase 3 Interventional

Chemotherapy With or Without Total-Body Irradiation Prior to Bone Marrow Transplantation in Treating Children With Acute Lymphoblastic Leukemia

NCT00002961
View directory record Official record
Conditions
Leukemia
Interventions
cyclophosphamide, cyclosporine, etoposide, methotrexate, allogeneic bone marrow transplantation, Total Body Irradiation, Busulfan, Mesna, Radiation
Drug · Procedure · Radiation
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Up to 21 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2001
U.S. locations
17
States / cities
Birmingham, Alabama • San Diego, California • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2013 · Synced Sep 26, 2026, 4:26 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)

NCT05568225
View directory record Official record
Conditions
Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R
Interventions
Etavopivat
Drug
Lead sponsor
Forma Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Miami, Florida • Ocala, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 26, 2026, 4:26 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Age of Blood in Sickle Cell Transfusion

NCT03704922
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Transfusion
Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Years to 60 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
3
States / cities
Atlanta, Georgia • Chapel Hill, North Carolina • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Sep 26, 2026, 4:26 PM EDT
Completed Phase 2 Interventional Results available

Revlimid in Transfusion Dependent Patients

NCT01178814
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
Revlimid (Lenalidomide)
Drug
Lead sponsor
Columbia University
Other
Eligibility
21 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2024 · Synced Sep 26, 2026, 4:26 PM EDT
Completed No phase listed Observational

Transfusion of Whole Blood and Cesarean Delivery: A Retrospective Review

NCT03523780
View directory record Official record
Conditions
Obstetric Labor Complications
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 18, 2020 · Synced Sep 26, 2026, 4:26 PM EDT
Recruiting Phase 3 Interventional

A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

NCT07422480
View directory record Official record
Conditions
Myelodysplastic Syndrome, Anemia
Interventions
Elritercept, Epoetin Alfa
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
31
States / cities
Gilbert, Arizona • Duarte, California • Santa Rosa, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 26, 2026, 4:26 PM EDT
Terminated Phase 3 Interventional

ALD-101 Adjuvant Therapy of Unrelated Umbilical Cord Blood Transfusion (UCBT) in Patients With Inherited Metabolic Diseases

NCT00654433
View directory record Official record
Conditions
Inherited Metabolic Diseases, Lysosomal Storage Disorders, Peroxisomal Storage Diseases, Inborn Errors of Metabolism, Mucopolysaccharidosis
Interventions
ALD-101
Biological
Lead sponsor
Aldagen
Industry
Eligibility
Up to 16 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
3
States / cities
Los Angeles, California • New York, New York • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 7, 2014 · Synced Sep 26, 2026, 4:26 PM EDT
Terminated Early Phase 1 Interventional

Pilot Study of Treatment for Subclinical AMR (Antibody-mediated Rejection) in Kidney Transplant Recipients

NCT03380936
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
Tacrolimus Extended Release Oral Tablet [Envarsus], Plasma Exchange and IVIG (Intravenous Immunoglobulin )
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 79 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 26, 2020 · Synced Sep 26, 2026, 4:26 PM EDT
No Longer Available No phase listed Expanded access

Aprotinin US Special Access Protocol

NCT00611845
View directory record Official record
Conditions
Postoperative Hemorrhage
Interventions
Aprotinin (Trasylol, BAYA0128)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
17
States / cities
Decatur, Alabama • Glendale, California • Pismo Beach, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2014 · Synced Sep 26, 2026, 4:26 PM EDT
Terminated Phase 1Phase 2 Interventional

Evaluation and Treatment of Iron Deficiency in Ovarian Cancer Patients

NCT03933813
View directory record Official record
Conditions
Epithelial Ovarian Cancer, Anemia, Iron Deficiency Anemia
Interventions
Iron Sucrose
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Sep 26, 2026, 4:26 PM EDT
Completed No phase listed Observational

Pulse Oximetry Measurement and Transfusions

NCT04249193
View directory record Official record
Conditions
Hypoxia Neonatal, Premature, Blood Transfusion
Interventions
Transfusion
Other
Lead sponsor
Christiana Care Health Services
Other
Eligibility
Up to 6 Weeks
Enrollment
75 participants
Timeline
2014 – 2017
U.S. locations
3
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 12, 2020 · Synced Sep 26, 2026, 4:26 PM EDT
Recruiting Phase 1 Interventional

Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies

NCT06647979
View directory record Official record
Conditions
Sickle Cell Disease, Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0), Beta-Thalassemia, Transfusion Dependent Beta-Thalassaemia
Interventions
autologous bone marrow derived CD34+ HSPCs electroporated with BCL11A enhancer targeting Cas9 ribonucleoprotein, Sequencing Assay for Variant rs114518452
Biological · Device
Lead sponsor
Daniel Bauer
Other
Eligibility
13 Years to 40 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Sep 26, 2026, 4:26 PM EDT
Terminated Phase 3 Interventional Results available

Stroke With Transfusions Changing to Hydroxyurea

NCT00122980
View directory record Official record
Conditions
Hemochromatosis, Cerebrovascular Accident, Anemia, Sickle Cell, Hematologic Diseases
Interventions
Red Cell Transfusions, Iron Chelation, Hydroxyurea, Phlebotomy
Procedure · Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
5 Years to 18 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
28
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Jacksonville, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2013 · Synced Sep 26, 2026, 4:26 PM EDT
Completed Phase 1Phase 2 Interventional

Use of Recombinant Adenovirus Therapy to Treat Localized Prostate Cancer

NCT01931046
View directory record Official record
Conditions
Localized Prostate Cancer
Interventions
Ad5-SGE-REIC/Dkk3
Drug
Lead sponsor
Momotaro-Gene Inc.
Industry
Eligibility
50 Years to 80 Years · Male only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
3
States / cities
San Diego, California • Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2020 · Synced Sep 26, 2026, 4:26 PM EDT
Recruiting Phase 1 Interventional

TLI, TBI, ATG & Hematopoietic Stem Cell Transplantation and Recipient T Regs Therapy in Living Donor Kidney Transplantation

NCT03943238
View directory record Official record
Conditions
Living Donor Kidney Transplantation
Interventions
Infusion of Donor Hematopoetic Stem Cells and Recipient Tregs
Biological
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
2
States / cities
Palo Alto, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 26, 2026, 4:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Decision Aid for Therapeutic Options In Sickle Cell Disease

NCT02326597
View directory record Official record
Conditions
Sickle Cell Disease, Sickle Cell Anemia, Hemoglobin SS, Hemoglobin SC, Hemoglobin Beta Thalassemia
Interventions
Decision Aid Tool, Standard Practice
Other
Lead sponsor
Emory University
Other
Eligibility
8 Years to 80 Years
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 8, 2018 · Synced Sep 26, 2026, 4:26 PM EDT
Withdrawn Not applicable Interventional

Patient-Driven Transfusion Thresholds in Hematological Disorders: A Pilot Study

NCT03086252
View directory record Official record
Conditions
Anemia, Aplastic Anemia, Bone Marrow Failure, Hematopoietic and Lymphoid Cell Neoplasm, Leukemia, Myelodysplastic Syndrome
Interventions
Red Blood Cell Transfusions (RBCT)
Procedure
Lead sponsor
Emory University
Other
Eligibility
19 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 25, 2018 · Synced Sep 26, 2026, 4:26 PM EDT
Terminated Phase 2 Interventional Results available

Erythropoietin to Prevent Unnecessary Transfusions In Patients With Cyanotic CHD - A Prospective Control Trial

NCT02564796
View directory record Official record
Conditions
Cyanotic Congenital Heart Disease, Anemia, Cyanosis, Congenital Heart Disease
Interventions
Epoetin Alfa and Iron, Iron
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
Up to 8 Weeks
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 1, 2021 · Synced Sep 26, 2026, 4:26 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Effect of Red Blood Cell Transfusion on Brain Metabolism in Patients With Subarachnoid Hemorrhage

NCT00968227
View directory record Official record
Conditions
Subarachnoid Hemorrhage, Vasospasm
Interventions
Red blood cell transfusion
Biological
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 16, 2017 · Synced Sep 26, 2026, 4:26 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Quantitative Susceptibility Mapping (QSM) to Guide Iron Chelating Therapy

NCT04171635
View directory record Official record
Conditions
MRI Scans
Interventions
Quantitative Susceptibility Mapping (QSM) Magnetic Resonance Imaging (MRI), R2* Magnetic Resonance Imaging (MRI)
Radiation
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
2 Years and older
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 26, 2026, 4:26 PM EDT
Active, not recruiting Early Phase 1 Interventional

Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide

NCT03910452
View directory record Official record
Conditions
Chronic Granulomatous Disease
Interventions
Busulfan, Alemtuzumab, Cyclophosphamide, Sirolimus, Total Body Irradiation, Allogeneic peripheral blood stem cell
Drug · Radiation · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
4 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2034
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 26, 2026, 4:26 PM EDT
Recruiting Phase 2 Interventional

Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers

NCT07087860
View directory record Official record
Conditions
Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis and Ureter Urothelial Carcinoma, Refractory Bladder Urothelial Carcinoma, Refractory Renal Pelvis and Ureter Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v7, Stage IV Renal Pelvis and Ureter Cancer AJCC v7
Interventions
Best Practice, Biospecimen Collection, Central Venous Cannula Insertion, Computed Tomography, Enfortumab Vedotin, Magnetic Resonance Imaging, Pembrolizumab, Plasmapheresis, Positron Emission Tomography, Questionnaire Administration, Antibody-Drug Conjugate Therapy
Other · Procedure · Drug + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 26, 2026, 4:26 PM EDT
Completed Phase 2 Interventional

Leucovorin for the Treatment of 5 q Minus Syndrome

NCT00004997
View directory record Official record
Conditions
5q Minus Syndrome, Myelodysplastic Syndrome
Interventions
Leucovorin
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 26, 2026, 4:26 PM EDT